GURUFOCUS.COM » STOCK LIST » Real Estate » REITs » BioMed Realty Trust Inc (NYSE:BMR) » Definitions » Beneish M-Score

BioMed Realty Trust (BioMed Realty Trust) Beneish M-Score : 0.00 (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is BioMed Realty Trust Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for BioMed Realty Trust's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of BioMed Realty Trust was 0.00. The lowest was 0.00. And the median was 0.00.


BioMed Realty Trust Beneish M-Score Historical Data

The historical data trend for BioMed Realty Trust's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMed Realty Trust Beneish M-Score Chart

BioMed Realty Trust Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.25 0.10 20.11 -2.34 -2.70

BioMed Realty Trust Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.30 -2.70 -2.79 13.09 5.47

Competitive Comparison of BioMed Realty Trust's Beneish M-Score

For the REIT - Office subindustry, BioMed Realty Trust's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMed Realty Trust's Beneish M-Score Distribution in the REITs Industry

For the REITs industry and Real Estate sector, BioMed Realty Trust's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioMed Realty Trust's Beneish M-Score falls into.



BioMed Realty Trust Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BioMed Realty Trust for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 10.2919+0.528 * 1.035+0.404 * 0.0436+0.892 * 1.0136+0.115 * 0.9951
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.308+4.679 * -0.039244-0.327 * 1.0212
=5.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep15) TTM:Last Year (Sep14) TTM:
Total Receivables was $196.6 Mil.
Revenue was 174.348 + 157.974 + 178.01 + 165.656 = $676.0 Mil.
Gross Profit was 112.279 + 102.704 + 119.363 + 112.212 = $446.6 Mil.
Total Current Assets was $710.1 Mil.
Total Assets was $6,460.7 Mil.
Property, Plant and Equipment(Net PPE) was $5,721.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $258.0 Mil.
Selling, General, & Admin. Expense(SGA) was $64.9 Mil.
Total Current Liabilities was $882.4 Mil.
Long-Term Debt & Capital Lease Obligation was $2,532.2 Mil.
Net Income was 28.203 + 23.578 + 17.345 + 140.349 = $209.5 Mil.
Non Operating Income was 16.331 + 29.089 + 13.037 + 124.033 = $182.5 Mil.
Cash Flow from Operations was 74.395 + 55.485 + 76.663 + 73.987 = $280.5 Mil.
Total Receivables was $18.8 Mil.
Revenue was 168.916 + 171.161 + 168.876 + 157.993 = $666.9 Mil.
Gross Profit was 114.017 + 117.525 + 116.353 + 108.102 = $456.0 Mil.
Total Current Assets was $52.7 Mil.
Total Assets was $6,238.3 Mil.
Property, Plant and Equipment(Net PPE) was $5,535.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $248.4 Mil.
Selling, General, & Admin. Expense(SGA) was $49.0 Mil.
Total Current Liabilities was $375.9 Mil.
Long-Term Debt & Capital Lease Obligation was $2,852.7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(196.562 / 675.988) / (18.843 / 666.946)
=0.290777 / 0.028253
=10.2919

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(455.997 / 666.946) / (446.558 / 675.988)
=0.683709 / 0.6606
=1.035

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (710.082 + 5721.247) / 6460.696) / (1 - (52.707 + 5535.115) / 6238.312)
=0.004545 / 0.104273
=0.0436

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=675.988 / 666.946
=1.0136

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(248.378 / (248.378 + 5535.115)) / (258.049 / (258.049 + 5721.247))
=0.042946 / 0.043157
=0.9951

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(64.919 / 675.988) / (48.97 / 666.946)
=0.096036 / 0.073424
=1.308

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2532.169 + 882.418) / 6460.696) / ((2852.669 + 375.933) / 6238.312)
=0.528517 / 0.517544
=1.0212

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(209.475 - 182.49 - 280.53) / 6460.696
=-0.039244

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

BioMed Realty Trust has a M-score of 5.47 signals that the company is likely to be a manipulator.


BioMed Realty Trust Beneish M-Score Related Terms

Thank you for viewing the detailed overview of BioMed Realty Trust's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioMed Realty Trust (BioMed Realty Trust) Business Description

Traded in Other Exchanges
N/A
Address
BioMed Realty Trust Inc, a Maryland corporation was formed on April 30, 2004 and commenced operations on August 11, 2004, after completing its initial public offering. The Company operates as a self-administered and self-managed real estate investment trust focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry mainly through its subsidiary, BioMed Realty, L.P., a Maryland limited partnership Its tenants mainly include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company's properties are generally located in markets with well established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/ New Jersey. The Company faces competition from various entities for investment opportunities in properties for life science tenants, including other REITs, such as health care REITs and suburban office property REITs, pension funds, insurance companies, investment funds and companies, partnerships, and developers. The Company's properties are subject to various laws, ordinances and regulations, including regulations relating to common areas.
Executives
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Brody William R Md Phd director MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Janice L. Sears director 1100 PARK PLACE, SUITE 200, SAN MATEO CA 94403
Alan D Gold director, officer: Chairman, President and CEO 17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Gary A Kreitzer director, officer: Exec VP and Assistant Sec 17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Margaret Faye Wilson director 12836 LUNADA PLACE, SAN DIEGO CA 92128
Griffin R Kent Jr officer: President and COO 5950 SHERRY LANE, SUITE 700, DALLAS TX 75225
Richard I Gilchrist director 5950 SHERRY LANE, SUITE 700, DALLAS TX 75225